CN105287903A - Treating medicine for subacute myelogenous leukemia - Google Patents
Treating medicine for subacute myelogenous leukemia Download PDFInfo
- Publication number
- CN105287903A CN105287903A CN201510845199.2A CN201510845199A CN105287903A CN 105287903 A CN105287903 A CN 105287903A CN 201510845199 A CN201510845199 A CN 201510845199A CN 105287903 A CN105287903 A CN 105287903A
- Authority
- CN
- China
- Prior art keywords
- parts
- subacute
- myelogenous leukemia
- radix
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a treating medicine for subacute myelogenous leukemia, belongs to the technical field of medicines, and solves the problem of treating the subacute myelogenous leukemia. Through traditional chinese medicine viewpoint analysis, the subacute myelogenous leukemia belongs to liver-kidney yin deficiency, blood and bone marrow invasion of wind toxin, and adopts a traditional Chinese medicine composition capable of dispelling wind, expelling toxin, tonifying kidney and generating marrow as the treating medicine. The treating medicine is composed of 15 parts of ginseng, 20 parts of astragalus membranaceus, 9 parts of periploca forrestii schltr, 10 parts of achyranthes bidentata, 15 parts of seaweed, 15 parts of loranthus parasiticus, 15 parts of red dates, 10 parts of Chinese wolfberry, 15 parts of rehmannia glutinosa, 10 parts of garden balsam stem, 10 parts of kudzuvine root, 15 parts of radix bupleuri, 12 parts of Chinese angelica, 10 parts of kadsura pepper stem and 8 parts of radix glycyrrhizae. The treating medicine for the subacute myelogenous leukemia is obvious in application and treatment effects.
Description
Technical field
The present invention relates to the medicine of subacute myelogenous leukemia, belong to medical art.
Background technology
Subacute myelogenous leukemia (being called for short sub-anxious grain) is a kind of anxious grain hypotype named in 1964 by Chinese scholar.FAB (method, state of American and Britain three) classification there is no sub-anxious grain, and in Chinese white disorders of blood classification typing symposium in 1986, built view includes anxious for Asia grain differentiated (M2b) hypotype of M2 in, to obtain the unification of classifying with FAB.Subacute granulocytic leukemia onset is comparatively slow, and early symptom is anemia, hemorrhage more rare, and spleen, liver and lymph node can not enlargement or only silght enlargements, and the course of disease is about 0.5-1 year; Hemogram often has pancytopenia, can see the immature granulocyte in each stage, and based on myelocyte, accompanies addicted to acid, basophilia, and platelet count is normal or reduce; Bone marrow smear granulocyte hypertrophy, erythrocyte and megakaryocytic series suppressed.Leukaemia is that obvious caryoplasm is grown uneven, and neutrophilic myelocyte kytoplasm is full of neutrophil granule at core recess, and karyon still has obvious kernel.Such cell > 30%.Clinical and the experimentation of subacute granulocytic leukemia (M2b).Find that subacute cell leukemia cell form is comparatively special after deliberation.Various histochemical staining positive material is lumps and is positioned at the recess of core; Easily special occlusion body is found under Electronic Speculum.Clinical disease course comparatively M2a is long, and morbidity is slow gradually, easily the outer marrow infiltrations such as nervous system occurs.
The treatment of subacute myelogenous leukemia, do not have specific medicine, but treatment also need not be acted with undue haste, numeration of leukocyte does not need to treat at once, because granulocyte mainly ripe in circulation the patient of 100 × below 109/L, its volume is little and have good deformability compared with germinal cell, and numeration of leukocyte need take active treatment measure 200 × more than 109/L person.Current to adopt cell toxicity medicament to make chemotherapy, obtain comparatively long-term chance for survival.The words of conditions permit can consider bone marrow transplantation.Adopt therapy of combining Chinese and Western medicine leukemia, can learn from other's strong points to offset one's weaknesses, Chinese medicine can make up doctor trained in Western medicine chemotherapy and not distinguish between the enemy and ourselves the deficiency of killing simply, can solve again the problem to chemotherapeutic drug resistance, simultaneously some aplastic leukemias, original white blood born of the same parents, platelet are very low, cannot stand powerful chemotherapeutic, useful Chinese medicine is treated, and has both avoided the toxic and side effects of Western medicine, again can mitigate the disease.
Summary of the invention
With Chinese medicine viewpoint analysis subacute myelogenous leukemia, belong to the hepatic and renal YIN deficiency, pathogenic wind toxic enters blood, invades bone marrow, that is intrinsic factor can not give birth to marrow by spermatogenesis for suffering from a deficiency of the kidney, then cause immunocompromised, diseases caused by exogenous pathogenic factor ailment said due to cold or exposure virus, malicious heresy is caved in an opponent's defence, injure bone marrow, treatment should with the scheme of the Chinese medicine combined therapy medicine of the toxin expelling that dispels the wind, tonifying the kidney to regenerate bone marrow.
The medicine of subacute myelogenous leukemia combines by each Chinese medicine quality part ratio below: Radix Ginseng 15 parts, the Radix Astragali 20 parts, Heiguteng exract 9 parts, Radix Achyranthis Bidentatae 10 parts, Sargassum 15 parts, Herba Taxilli 15 parts, Fructus Jujubae 15 parts, Fructus Lycii 10 parts, 15 parts, Radix Rehmanniae Preparata, Herba speranskiae tuberculatae 10 parts, Radix Puerariae 10 parts, Radix Bupleuri 15 parts, Radix Angelicae Sinensis 12 parts, Caulis Piperis Kadsurae 10 parts, 8 parts, Radix Glycyrrhizae.
Below each Chinese medicinal ingredients property of medicine effect in the mixing Chinese medicine for the treatment of subacute myelogenous leukemia is performed an analysis.Radix Ginseng has strongly invigorating primordial QI, and multiple arteries and veins takes off admittedly, and invigorating the spleen to benefit the lung, promotes the production of body fluid, the effect of calming the nerves; Radix Ginseng is containing 10 multiclass ginsenosides, and saccharide, and multiclass aminoacid and vitamin etc., have arrhythmia, the effect of anti-senility.The Radix Astragali has effect that benefiting QI for strengthening the superficies, arresting sweating are admittedly de-, hold in the palm skin ulcer granulation promoting, inducing diuresis to remove edema; Be used for the treatment of the deficiency of vital energy weak, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, carbuncle difficulty is burst, and bursts for a long time and does not hold back.Heiguteng exract effect: the meridian dredging, curing rheumatism, invigorate blood circulation, antiinflammatory; Energy expelling wind and removing dampness, removing obstruction in the collateral to relieve pain; For anemofrigid-damp arthralgia, brachialgia, lumbago, have a pain in the leg the diseases such as pain.Radix Achyranthis Bidentatae dissipating blood stasis blood, subduing inflammation, invigorating the liver and kidney, bone and muscle strengthening, controls waist kneecap pain.Sargassum effect: softening the hard mass, expectorant, diuretic, expels the heat-evil; Control scrofula, goiter, gather, edema, painful and swollen testis.Herba Taxilli returns liver, kidney channel; For invigorating the liver and kidney; Bone and muscle strengthening; Wind-damp dispelling; Antiabortive; Main soreness of waist and knee joint; Muscles and bones flaccidity is weak; Limbs are hemiplegia; Rheumatic arthralgia; Head is wrong dizzy; Frequent fetal movement, metrostaxis.Red jujube blood-enriching benefit blood, invigorating spleen and reinforcing stomach, invigorating the spleen and replenishing QI.Fructus Lycii energy the kidney invigorating and essence nourishing, nourishing the liver to improve visual acuity, blood-enriching tranquillizing, promoting the production of body fluid to quench thirst, nourishing the lung to arrest cough.Radix Rehmanniae Preparata sweet in the mouth tepor matter is moistened, YIN nourishing, vital essence replenishing and marrow benifiting, is equipped with Radix Angelicae Sinensis and mends treatment Blood deficiency.Herba speranskiae tuberculatae has expelling wind and dampness, promoting blood circulation and stopping pain; Relaxing muscles and tendons and activating QI and blood in the collateral, expelling wind and dampness, promoting blood circulation and stopping pain, softening the hard mass disappears painful abdominal mass.Radix Puerariae has heat-clearing and toxic substances removing, promoting the production of body fluid to quench thirst, kidney and spleen invigorating, stomach reinforcing to calm the nerves, the improving eyesight that clears away heart-fire, intestine moistening road just and the function such as relieving alcoholic intoxication.Radix Bupleuri effect: with in table solution, soothing the liver, yang invigorating; For: cold, fever, alternate attack of chill and fever, distending pain in the chest and hypochondrium, menoxenia, prolapse in palace, proctoptosis.Chinese angelica blood supplementing and blood, menstruction regulating and pain relieving, moisturizes laxation, for blood deficiency, shallow complexion, dizzy cardiopalmus; Blood deficiency, or have the stagnant menoxenia of the stasis of blood, amenorrhea, dysmenorrhea concurrently, deficient cold type stomachache, angina pectoris, rheumatic arthralgia.Radix Angelicae Sinensis spleen invigorating, tonifying the lung, reinforces the kidney, and benefit essence, controls diarrhea due to hypofunction of the spleen, chronic dysentery, cough due to consumptive disease, quench one's thirst, and seminal emission, leukorrhagia, frequent micturition, spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, the kidney invigorating arresting seminal emission.Caulis Piperis Kadsurae is the key medicine of wind-damp dispelling, the meridian dredging, effective for rheumatism arthromyodynia.Radix Glycyrrhizae invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The medicine beneficial effect of the invention of subacute myelogenous leukemia is: by with Chinese medicine viewpoint analysis subacute myelogenous leukemia, belong to the hepatic and renal YIN deficiency, pathogenic wind toxic enters blood, invades bone marrow, that is intrinsic factor can not give birth to marrow by spermatogenesis for suffering from a deficiency of the kidney, then cause immunocompromised, diseases caused by exogenous pathogenic factor ailment said due to cold or exposure virus, poison heresy is caved in an opponent's defence, injure bone marrow, to take to dispel the wind the scheme of Chinese medicine combined therapy medicine of toxin expelling, tonifying the kidney to regenerate bone marrow, tcm theory analysis is correct, and medicine coordinates correct, application for the treatment of Be very effective, stable.
Detailed description of the invention
Below to be applicable to a dose drug that a subacute myelogenous leukemia patient takes as preferred embodiment further instruction.
It is combine by each Chinese medicine quality below that the medicine of subacute myelogenous leukemia is applicable to a dosage dose that a subacute myelogenous leukemia patient takes: Radix Ginseng 15 grams, the Radix Astragali 20 grams, Heiguteng exract 9 grams, Radix Achyranthis Bidentatae 10 grams, Sargassum 15 grams, Herba Taxilli 15 grams, Fructus Jujubae 15 grams, Fructus Lycii 10 grams, 15 grams, Radix Rehmanniae Preparata, Herba speranskiae tuberculatae 10 grams, Radix Puerariae 10 grams, Radix Bupleuri 15 grams, Radix Angelicae Sinensis 12 grams, Caulis Piperis Kadsurae 10 grams, 8 grams, Radix Glycyrrhizae.
The medicine using method of subacute myelogenous leukemia: decoct soup and take orally, patient with severe symptoms takes dose day, and patient with slight symptoms suitably can reduce dose, takes five dosage and can obtain improved effect.Follow-up investigation is taken, treatment improvement effective percentage 100%, cure rate 95%, stable curative effect, use safety through 20 many cases subacute myelogenous leukemia patient clinicals.
Claims (1)
1. the medicine of subacute myelogenous leukemia, is characterized in that combining by each Chinese medicine quality part ratio below: Radix Ginseng 15 parts, the Radix Astragali 20 parts, Heiguteng exract 9 parts, Radix Achyranthis Bidentatae 10 parts, Sargassum 15 parts, Herba Taxilli 15 parts, Fructus Jujubae 15 parts, Fructus Lycii 10 parts, 15 parts, Radix Rehmanniae Preparata, Herba speranskiae tuberculatae 10 parts, Radix Puerariae 10 parts, Radix Bupleuri 15 parts, Radix Angelicae Sinensis 12 parts, Caulis Piperis Kadsurae 10 parts, 8 parts, Radix Glycyrrhizae.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510845199.2A CN105287903A (en) | 2015-11-27 | 2015-11-27 | Treating medicine for subacute myelogenous leukemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510845199.2A CN105287903A (en) | 2015-11-27 | 2015-11-27 | Treating medicine for subacute myelogenous leukemia |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105287903A true CN105287903A (en) | 2016-02-03 |
Family
ID=55186186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510845199.2A Withdrawn CN105287903A (en) | 2015-11-27 | 2015-11-27 | Treating medicine for subacute myelogenous leukemia |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105287903A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728369A (en) * | 2016-12-15 | 2017-05-31 | 防城港市蓝瀚达科技有限公司 | One group of Chinese medicine for effectively treating leukaemia |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1260983A (en) * | 1999-01-21 | 2000-07-26 | 仇殿明 | Process for preparing leukemia medicines |
CN102048977A (en) * | 2011-01-12 | 2011-05-11 | 徐祖书 | Chinese medicinal composition for treating chronic myeloid leukemia |
CN105012632A (en) * | 2015-07-30 | 2015-11-04 | 陈维松 | Mixed traditional Chinese medicine for treating chronic myeloid leukemia |
-
2015
- 2015-11-27 CN CN201510845199.2A patent/CN105287903A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1260983A (en) * | 1999-01-21 | 2000-07-26 | 仇殿明 | Process for preparing leukemia medicines |
CN102048977A (en) * | 2011-01-12 | 2011-05-11 | 徐祖书 | Chinese medicinal composition for treating chronic myeloid leukemia |
CN105012632A (en) * | 2015-07-30 | 2015-11-04 | 陈维松 | Mixed traditional Chinese medicine for treating chronic myeloid leukemia |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728369A (en) * | 2016-12-15 | 2017-05-31 | 防城港市蓝瀚达科技有限公司 | One group of Chinese medicine for effectively treating leukaemia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104107318A (en) | Traditional Chinese medicinal composition for treating blood stasis stagnation type irregular menstruation | |
CN101524464B (en) | Pure traditional Chinese medicine composition for treating female breast diseases and pure traditional Chinese medicine preparation prepared thereby | |
CN104474471A (en) | Traditional Chinese medicine composition for treating thyroid | |
CN100512847C (en) | Chinese traditional medicine compound took orally for treating cervical spondylosis | |
CN104383390A (en) | Chinese traditional medicine preparation for treating lung cancer | |
CN103536748A (en) | Traditional Chinese medicament for treating goiter with depression of liver to generate pathogenic fire | |
CN102512617A (en) | Chinese herbal preparation for treating psoriasis | |
CN103495019A (en) | Heart-nourishing and nerve-soothing traditional Chinese medicine preparation as well as preparation method thereof | |
CN106266896A (en) | A kind of invigorating primordial QI, kidney invigorating and YANG supporting, bone and muscle strengthening, the pill of curing rheumatism | |
CN102366601A (en) | Traditional Chinese medicine preparation for treating apoplexia, facial paralysis and hemiplegia | |
CN105362904A (en) | Qi tonifying and blood nourishing traditional Chinese medicinal pill and preparation method thereof | |
CN102357228B (en) | Traditional Chinese medicine combination for treating liver diseases | |
CN104721758A (en) | Pharmaceutical for treating ovarian cyst and preparing method thereof | |
CN105287903A (en) | Treating medicine for subacute myelogenous leukemia | |
CN103830591A (en) | Traditional Chinese medicine formula for treating stroke and post-traumatic brain syndrome and preparation method of traditional Chinese medicine | |
CN104069463B (en) | A kind of Chinese drugs agentia for treating gynaecologic metrorrhagia | |
CN105477619A (en) | Traditional Chinese medicine composition for treating delayed menorrhea | |
CN104940885A (en) | Traditional Chinese medicine for treating dysfunction of endocrine | |
CN104800491A (en) | Oral solution with superstrong function of improving human immunity | |
CN104116912A (en) | Traditional Chinese medicinal composition for rehabilitation after radiotherapy and chemotherapy of tumor patients | |
CN103784689A (en) | Medicinal composition for treating leukemia | |
CN103127295B (en) | One is treated leukemic Chinese medicine | |
CN102961454A (en) | Method for treating scapulohumeral periarthritis and preparation method for same | |
CN105535545A (en) | Traditional Chinese medicine preparation for treating thrombopenia caused by benzene poisoning | |
CN105031108A (en) | Medicine for treating chronic amyotrophic lateral sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160203 |